Virax Biolabs (VRAX) announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRAX:
- Virax Biolabs Sees Asset Growth Amid Financial Loss
- Virax Biolabs Sets Date for 2024 AGM
- Virax Biolabs Expands Reach with Europa Biosite Deal
- Virax Biolabs announces distribution agreement with Europa Biosite
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
